文献速递妇科

早期宫颈癌保留生育功能手术中宫颈锥切联合淋巴结评估的趋势增加

Increasing trends of cervical conization with lymph node evaluation for fertility-sparing surgery in early cervical cancer.
PubMed 文献 · Gynecol Oncol · 2023-05-01

该回顾性队列研究基于美国国家癌症研究所监测、流行病学和最终结果计划数据,纳入2004至2019年407例50岁以下IA-IB2期(≤4 cm)接受保留生育功能手术的宫颈癌患者。宫颈锥切联合淋巴结评估组从2004-2007年的43.5%增至2016-2019年的58.4%(P-trend=0.005),且与根治性宫颈切除联合淋巴结评估组总生存相当(7年生存率98.9% vs 97.8%)。

要点

  • 2004至2019年50岁以下IA-IB2期宫颈癌保留生育功能手术中,宫颈锥切联合淋巴结评估比例从43.5%升至58.4%(P-trend=0.005)。
  • 宫颈锥切联合前哨淋巴结活检比例从0%升至14.4%(P-trend<0.001)。
  • 倾向评分加权模型中,宫颈锥切联合淋巴结评估组与根治性宫颈切除联合淋巴结评估组7年总生存率分别为98.9%和97.8%。

核心结论

  • 基于人群的分析提示,对于希望保留生育功能的早期宫颈癌患者,宫颈锥切联合淋巴结评估(尤其是前哨淋巴结活检)的应用逐渐增加。

研究设计与样本

  • 回顾性队列研究,使用美国国家癌症研究所监测、流行病学和最终结果计划数据,纳入2004至2019年407例50岁以下IA-IB2期(≤4 cm)接受保留生育功能手术的宫颈癌患者。
  • 暴露为保留生育功能手术类型:宫颈锥切联合淋巴结评估(Cone-LN,n=196)或根治性宫颈切除联合淋巴结评估(Trach-LN,n=211)。

主要发现

  • 接受宫颈锥切联合淋巴结评估的患者比例从2004-2007年的43.5%增加至2016-2019年的58.4%(P-trend=0.005)。
  • 接受宫颈锥切联合前哨淋巴结活检的患者比例从0%增加至14.4%(P-trend<0.001)。
  • 多变量分析中,宫颈锥切联合淋巴结评估组相比根治性宫颈切除联合淋巴结评估组更可能接受前哨淋巴结活检(aOR 6.04)。
  • 腺癌(aOR 0.49)和T1b肿瘤(≤2 cm aOR 0.21,2.1-4.0 cm aOR 0.10)患者接受宫颈锥切联合淋巴结评估的可能性较低。
  • 倾向评分加权模型中,宫颈锥切联合淋巴结评估组与根治性宫颈切除联合淋巴结评估组总生存相当(7年生存率98.9% vs 97.8%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine uptake, characteristics, and survival outcome of less-radical fertility-sparing surgery with cervical conization and lymph node evaluation (Cone-LN) in reproductive age patients with early cervical cancer. METHODS: This retrospective cohort study examined the National Cancer Institute's Surveillance, Epidemiology, and End Results Program. The study population included 407 patients aged <50 years with stage IA-IB2 (≤4 cm) cervical cancer who received fertility-sparing surgery from 2004 to 2019. The exposure was fertility-sparing surgery type: Cone-LN (n = 196) or trachelectomy with lymph node evaluation (Trach-LN, n = 211). The main co-outcomes were (i) temporal trends of surgery type, assessed with Cochran-Armitage test, and (ii) clinical and tumor characteristics, assessed with multivariable binary logistic regression model. The secondary outcome was overall survival, assessed with inverse probability of treatment weighting propensity score. RESULTS: The number of patients receiving Cone-LN increased from 43.5% in 2004-2007 to 58.4% in 2016-2019 (P-trend = 0.005). Patients receiving conization and sentinel lymph node (SLN) biopsy alone increased from 0% to 14.4% (P-trend < 0.001). In a multivariable analysis, patients in the Cone-LN group were more likely to undergo SLN biopsy (aOR 6.04) compared to those in the Trach-LN group whereas those with adenocarcinoma (aOR 0.49) and T1b tumors (aOR for ≤2 cm 0.21, and aOR for 2.1-4.0 cm 0.10) were less likely to receive Cone-LN. In a propensity score-weighted model, the Cone-LN and Trach-LN groups had comparable overall survival (7-year rates, 98.9% vs 97.8%). Similar associations were observed for patients with squamous, adenocarcinoma / adenosquamous, T1a classification, and T1b(≤2 cm) classification. CONCLUSION: The current population-based analysis suggests that the performance of cervical conization with lymph node evaluation, particularly with SLN biopsy, is gradually increasing for early cervical cancer patients desiring future fertility.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Furey KB, Anderson ZS, Kuznicki ML, et al. Increasing trends of cervical conization with lymph node evaluation for fertility-sparing surgery in early cervical cancer. Gynecol Oncol. 2023. PMID: 37137189. doi:10.1016/j.ygyno.2023.04.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。